The National Institute on Neurological Disorders and Stroke (NINDS) intends to modify an existing sole-source contract with Curia Global, Inc. to increase the contract maximum by $30,145,159, raising it from $39,500,000 to $69,645,159. This modification supports the continuation of medicinal chemistry services for therapeutic development, including SAR analysis, synthesis, ADMET studies, and compound logistics, essential for advancing preclinical candidates toward IND filings. The contract’s ordering period remains unchanged, running from March 16, 2018, to March 15, 2028. Services are performed to support NIH programs, primarily focused on neurotherapeutics, with the location of performance not specified. No budget amounts beyond the stated contract increase are provided.